Last reviewed · How we verify
Imiquimod Vehicle
Imiquimod vehicle is a topical formulation base designed to deliver imiquimod, a toll-like receptor 7/8 agonist that activates innate immune responses.
Imiquimod vehicle is a topical formulation base designed to deliver imiquimod, a toll-like receptor 7/8 agonist that activates innate immune responses. Used for Actinic keratosis, Basal cell carcinoma, Genital warts.
At a glance
| Generic name | Imiquimod Vehicle |
|---|---|
| Sponsor | Apotex Inc. |
| Drug class | Toll-like receptor agonist |
| Target | TLR7/TLR8 |
| Modality | Small molecule |
| Therapeutic area | Dermatology/Immunology |
| Phase | Phase 3 |
Mechanism of action
The vehicle component serves as the pharmaceutical carrier for imiquimod, enabling topical delivery to skin lesions. Imiquimod itself works by binding to TLR7 and TLR8 on immune cells, triggering interferon and cytokine production that enhances local immune responses against viral infections and abnormal cells. The vehicle formulation optimizes drug penetration and retention at the site of application.
Approved indications
- Actinic keratosis
- Basal cell carcinoma
- Genital warts
Common side effects
- Local skin irritation
- Erythema
- Pruritus
- Erosion
Key clinical trials
- Basal Cell Carcinoma Chemoprevention Trial (PHASE3)
- Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch (NA)
- Topical Application of Imiquimod Gel at Different Concentrations in Actinic Cheilitis (PHASE1)
- A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients (PHASE2)
- Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts (PHASE4)
- Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions (PHASE3)
- Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients (PHASE2)
- Efficacy and Tolerability of Topical LFX453 for External Genital Warts (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imiquimod Vehicle CI brief — competitive landscape report
- Imiquimod Vehicle updates RSS · CI watch RSS
- Apotex Inc. portfolio CI